AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 221 min read$TMO

TD Cowen maintains Buy rating on Thermo Fisher Scientific, $810 price target

TD Cowen kept a Buy rating on Thermo Fisher Scientific with an $810 price target, suggesting a 16.7% upside. The company reported 6% organic revenue growth in Q3, raised full-year guidance, and expects margin expansion. According to TD Cowen, this reflects strong demand and operational efficiency.

Original reporting
tradingview.com
Published Oct 22, 2026, 2:38 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 2:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
TD Cowen maintains Buy rating on Thermo Fisher Scientific, $810 price target — source image
Source · tradingview.com
Decision brief

The 30-second read

$TMOBullishMed
01

Why it matters

Analyst upgrade with a $810 price target signals confidence in sustained demand and margin expansion.

02

Market read

Guidance lift for a large-cap healthcare company can drive short‑term buying interest and influence sector sentiment.

03

What to watch

Potential supply‑chain constraints or regulatory risks could temper the upside.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Thermo Fisher reported 6% organic Q3 revenue growth and raised full‑year outlook.

Company-level read

Ticker impact

$TMOBullishHigh confidence
Context

Thermo Fisher raised full-year revenue and EPS guidance and added an $810 price target, indicating stronger outlook.

Expected impact

upward pressure as investors price in higher revenue and EPS expectations

Evidence & confidence

Analyst upgrade with concrete guidance numbers typically moves the stock higher on the day of release.

Market effects

Sector

Life‑sciences and diagnostics sector may see broader optimism from the guidance beat.

Regional

U.S. markets could see a modest lift in healthcare indices.

Global

Limited to investors tracking large-cap biotech and industrials.

Counterpoint

What could challenge this read

If the guidance upgrade is already priced in, the stock could face short‑term profit‑taking.

Key entities

  • company
    Thermo Fisher Scientific

    Global provider of scientific instruments and services.

  • analyst
    TD Cowen

    Equity research firm maintaining a Buy rating.

Read at source← All news

Related articles

OCT 22
$COFHighAI 8/10

Company News for Oct 22, 2026

Capital One (COF) shares rose 2.5% after reporting Q3 2026 adjusted earnings of $6.69 per share, beating estimates. Bank OZK (OZK) shares gained 4.2% with $1.50 per share earnings, surpassing expectations. Thermo Fisher (TMO) shares increased 1% with $6.68 per share earnings, exceeding estimates. Danaher (DHR) shares climbed 4.3% with $2.11 per share earnings, outpacing forecasts.

finance.yahoo.com1 min
OCT 22
$TMOHighAI 8/10

Thermo Fisher Scientific Hits $12.14 Billion in Q3 Revenue as Innovation Fuels Double-Digit Earnings Growth

Thermo Fisher Scientific reported Q3 2026 revenue of $12.14 billion, up 9% YoY, with organic growth of 6%. GAAP EPS rose 9% to $4.64, while adjusted EPS increased 15% to $6.68. The company attributed growth to innovation and strategic initiatives, including new product launches and partnerships. According to CEO Marc Casper, the results reflect strong execution and a proven growth strategy.

biospectrumasia.com2 min
OCT 22
$TMOHighAI 9/10

TMO Q3 deep dive: pharma demand, AI integration, and end-market recovery drive momentum

Thermo Fisher (TMO) reported Q3 2026 revenue of $12.14B, up 9.1% YoY, and EPS of $6.68, beating estimates. Growth was driven by pharma services, electron microscopy, and AI integration. Management expects continued momentum in pharma and biotech, with AI enhancing productivity and customer offerings. The company's market cap is $256.6B, and shares are trading at $697.65.

tradingview.com3 min
OCT 22
$SMCIHighAI 8/10

US Stocks Mixed as Super Micro, Equifax, Hasbro Jump

Super Micro (SMCI) rose 9.67% on stronger-than-expected revenue outlook, projecting $18.5B-$19.5B for Q1. Hasbro (HAS) gained 1.26% after Q3 earnings beat estimates by 55.91%. Equifax (EFX) surged 10.7% on Q3 results, despite lowering full-year revenue guidance. AT&T (T) shares fell 5.96% despite raising 2026 earnings guidance.

hdfcsky.com3 min